Florida Cancer Specialists Highlights Role in Development of Polatuzumab Vedotin Plus R-CHP in DLBCL
May 10th 2023Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?
May 6th 2023For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
TPG, AmerisourceBergen Acquire OneOncology in Deal Valued at $2.1 Billion
April 20th 2023Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.